CDK 4/6 Inhibitors in HR+/HER2- Breast Cancer – Nashville, TN
Meharry Medical College 1005 Dr. D.B.Todd Jr. Blvd, Nashville, TN, United StatesThis program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.